# Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

> **NCT04565665** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 70 (estimated)

## Conditions studied

- COVID-19 Infection
- COVID-19-Associated Acute Respiratory Distress Syndrome
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Symptomatic COVID-19 Infection Laboratory-Confirmed

## Interventions

- **OTHER:** Best Practice
- **BIOLOGICAL:** Mesenchymal Stem Cell

## Key facts

- **NCT ID:** NCT04565665
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-29
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04565665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04565665, "Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04565665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*